Skip to main content

Table 1 Study descriptive characteristics

From: Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

Characteristic Controls Cases Total p-value
n (col %) n (col %) n (col %)
Gender
Female 151(59.2) 28(32.9) 179(52.6)  < 0.001
Male 104(40.8) 57(67.1) 161(47.4)  
Total 255(100) 85(100) 340(100)  
Type of second-line drug
lopinavir 241(94.5) 71(83.5) 312(91.8) 0.001
Atazanavir 8(3.1) 4(4.7) 12(3.5)  
Other PIµ 6(2.4) 10(11.8) 16(4.7)  
Total 255(100) 85(100) 340(100)  
TB treatment§
No 246(97.2) 71(83.5) 317(93.8)  < 0.001
YES 7(2.8) 14(16.5) 21(6.2)  
Total 253(100) 85(100) 338(100)  
Year of ART initiation
Before 2001 7(2.7) 23(27.1) 30(8.8)  < 0.001
2001–2005 170(66.7) 41(48.2) 211(62.1)  
2006–2010 64(25.1) 19(22.4) 83(24.4)  
2011–2015 14(5.5) 2(2.4) 16(4.7)  
Total 255(100) 85(100) 340(100)  
Type of first-line drug
NNRTI based 217(85.1) 66(77.6) 283(83.2) 0.111
NON-NNRTI 38(14.9) 19(22.4) 57(16.8)  
Total 255(100) 85(100) 340(100)  
Other comorbidities §
No 226(89.3) 76(89.4) 302(89.3) 0.983
Yes 27(10.7) 9(10.6) 36(10.7)  
Total 253(100) 85(100) 338(100)  
Age at start of 2nd line: median (IQR)
  38(32–46) 38(31–46) 38(32–46) 0.300
CD4 at start of 2nd line: median (IQR)
  130(62–250) 68.5(18–181) 115(41–234) 0.079
VL at start of 2nd line: median (IQR)¥
  43,005.5(13,645.5–135,553.5) 233,700(65,985.5–601,989) 67,965(18,846.5–189,160)  < 0.001
Duration on 1st line: median (IQR)
  4 (2 – 5) 3 (2–6) 3 (2–5) 0.210
  1. §Missing data on two observations, ¥ Missing data on 128 observations, TB: Tuberculosis, VL: Viral Load, IQR: Interquartile Range, ∞Non-NRTI: triple nucleosides, µ “other PI”: saquinavir and nelfinavir